 PHILADELPHIA, March 22, 2021 GLOBE NEWSWIRE -- Passage Bio, Inc. Nasdaq: PASG, a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system CNS disorders, today announced it has appointed Eliseo O. Salinas, M.D., MSc, as the companys chief research development RD officer. Dr. Salinas joins the company from Acadia Pharmaceuticals, where he served as chief scientific officer CSO and senior vice president, External Innovation. 